CO5170501A1 - AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO - Google Patents
AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEOInfo
- Publication number
- CO5170501A1 CO5170501A1 CO00026470A CO00026470A CO5170501A1 CO 5170501 A1 CO5170501 A1 CO 5170501A1 CO 00026470 A CO00026470 A CO 00026470A CO 00026470 A CO00026470 A CO 00026470A CO 5170501 A1 CO5170501 A1 CO 5170501A1
- Authority
- CO
- Colombia
- Prior art keywords
- carbon atoms
- alkyl
- halogen
- optionally substituted
- atoms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
La presente invención se relaciona con un compuesto de la fórmula I :<EMI FILE="00026470_1" ID="1" IMF=JPEG >en donde: a es N o C;b es CH cuando a es N, u O cuando a es C;--- denota un enlace sencillo o doble, dependiendo de si el anillo de azol es un anillo de imidazol o de oxazol;Z es N o CH;W es -NR6-Y-, -O-, ó -S-,en donde R6 es H, alquilo de 1 a 4 átomos de carbono, cicloalquilo de 3 a 8 átomos de carbono, cicloalquilo de 3 a 8 átomos de carbono-alquilo de 1 a 3 átomos de carbono, arilo de 6 a 18 átomos de carbono, heteroarilo de 3 a 18 átomos de carbono, aralquilo de 7 a 19 átomos de carbono, o heteroaralquilo de 4 a 19 átomos de carbono, e - Y - es alquileno de 1 a 4 átomos de carbono, o un enlace directo;R2 es fenilo, opcionalmente sustituido por uno o más sustituyentes, cada uno de los cuales se selecciona independientemente a partir de halógeno, CF3, ciano, amido, o tioamido, carboxilato o tiocarboxilato, alcoxilo de 1 a 4 átomos de carbono, alquilo de 1 a 4 átomos de carbono, o NH2 que está opcionalmente sustituido por mono- o di-N-alquilo de 1 a 4 átomos de carbono;R3 es H, halógeno, alquilo de 1 a 10 átomos de carbono, cicloalquilo de 3 a 10 átomos de carbono, heterocicloalquilo de 3 a 18 átomos de carbono, arilo de 6 a 18 átomos de carbono, heteroarilo de 3 a 18 átomos de carbono, o metilenaminoguanidinilo (es decir, -CH=N-NH-C(NH).NH2), cada uno de los cuales está opcionalmente sustituido por hasta cuatro sustituyentes seleccionados por separado a partir de alquilo de 1 a 4 átomos de carbono, halógeno, alquilo de 1 a 4 átomos de carbono sustituido por halógeno, hidroxilo, alcoxilo de 1 a 4 átomos de carbono, tioalquilo de 1 a 4 átomos de carbono, o amino opcionalmente sustituido por mono- o di-N-alquilo de 1 a 4 átomos de carbono, o por N-heterociclilo que contiene de 5 a 7 átomos del anillo, y que contiene opcionalmente un heteroátomo adicional;R5 es arilo de 6 a 18 átomos de carbono, heteroarilo de 3 a 18 átomos de carbono, o cicloalquilo de 3 a 12 átomos de carbono, cada uno de los cuales está opcionalmente sustituido por hasta cuatro sustituyentes seleccionados por separado a partir de alquilo de 1 a 4 átomos de carbono, halógeno, alquilo de 1 a 4 átomos de carbono sustituido por halógeno, hidroxilo, alcoxilo de 1 a 4 átomos de carbono, tioalquilo de 1 a 4 átomos de carbono, o amino opcionalmente sustituido por mono- o di-N-alquilo de 1 a 4 átomos de carbono, o por N-heterociclilo que contiene de 5 a 7 átomos del anillo, y que opcionalmente contiene un heteroátomo adicional, o un ésteres del mismo y sales de adición de ácido del mismo. Igualmente, se refiere a una composición farmacéutica que contiene dicho compuesto y el proceso para la preparación del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9908532.6A GB9908532D0 (en) | 1999-04-14 | 1999-04-14 | Organic compounds |
GBGB9908531.8A GB9908531D0 (en) | 1999-04-14 | 1999-04-14 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5170501A1 true CO5170501A1 (es) | 2002-06-27 |
Family
ID=26315413
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO00026470A CO5170501A1 (es) | 1999-04-14 | 2000-04-11 | AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO |
Country Status (25)
Country | Link |
---|---|
US (1) | US6579874B2 (es) |
EP (1) | EP1224180B1 (es) |
JP (1) | JP2003503311A (es) |
KR (1) | KR20010108504A (es) |
CN (1) | CN1378544A (es) |
AR (1) | AR023465A1 (es) |
AT (1) | ATE244236T1 (es) |
AU (1) | AU4295300A (es) |
BR (1) | BR0010598A (es) |
CA (1) | CA2370417A1 (es) |
CO (1) | CO5170501A1 (es) |
CZ (1) | CZ20013696A3 (es) |
DE (1) | DE60003709T2 (es) |
DK (1) | DK1224180T3 (es) |
ES (1) | ES2202114T3 (es) |
HU (1) | HUP0302747A2 (es) |
IL (1) | IL145836A0 (es) |
MX (1) | MXPA01010434A (es) |
NO (1) | NO20014987L (es) |
PE (1) | PE20010031A1 (es) |
PL (1) | PL364789A1 (es) |
PT (1) | PT1224180E (es) |
SK (1) | SK14562001A3 (es) |
TR (1) | TR200102967T2 (es) |
WO (1) | WO2000063204A2 (es) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60039059D1 (de) | 1999-10-07 | 2008-07-10 | Amgen Inc | Triazin-kinase-hemmer |
AU7922900A (en) | 1999-10-27 | 2001-05-08 | Novartis Ag | Thiazole and imidazo (4,5-b) pyridine compounds and their pharmaceutical use |
AU3704101A (en) | 2000-02-17 | 2001-08-27 | Amgen Inc | Kinase inhibitors |
IL156306A0 (en) | 2000-12-21 | 2004-01-04 | Glaxo Group Ltd | Pyrimidineamines as angiogenesis modulators |
CA2436739A1 (en) * | 2000-12-26 | 2002-07-04 | Takeda Chemical Industries, Ltd. | Combination agent |
WO2002062792A1 (fr) * | 2001-02-02 | 2002-08-15 | Takeda Chemical Industries, Ltd. | Inhibiteur de jnk |
CN1496366A (zh) | 2001-03-09 | 2004-05-12 | �Ʒ� | 作为抗炎剂的***并吡啶 |
WO2002072576A1 (en) * | 2001-03-09 | 2002-09-19 | Pfizer Products Inc. | Benzimidazole anti-inflammatory compounds |
DE60205974T2 (de) | 2001-04-04 | 2006-06-29 | Pfizer Products Inc., Groton | Neue Benzotriazole mit entzündungshemmender Wirkung |
WO2002100433A1 (en) * | 2001-06-11 | 2002-12-19 | Takeda Chemical Industries, Ltd. | Medicinal compositions |
US7109216B2 (en) | 2001-09-21 | 2006-09-19 | Solvay Pharmaceuticals B.V. | 1H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
TWI231757B (en) * | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
CA2456606C (en) | 2001-09-21 | 2010-01-26 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
US7473695B2 (en) * | 2001-10-22 | 2009-01-06 | Mitsubishi Tanabe Pharma Corporation | 4-imidazolin-2-one compounds |
EP1458385A4 (en) * | 2001-12-19 | 2005-12-21 | Merck & Co Inc | HETEROARYLE SUBSTITUTED IMIDAZOLES MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR TYPE 5 |
AR039241A1 (es) * | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
EP1707205A2 (en) | 2002-07-09 | 2006-10-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases |
IL166510A0 (en) | 2002-08-09 | 2006-01-15 | Nps Pharma Inc | 1,2,4"oxadiazole as modulators of metabotropic glutamate receptor-5 |
WO2004014370A2 (en) * | 2002-08-09 | 2004-02-19 | Astrazeneca Ab | Oxadiazoles as modulators of metabotropic glutamate receptor-5 |
CA2495179A1 (en) | 2002-08-09 | 2004-02-19 | Astrazeneca Ab | Compounds having an activity at metabotropic glutamate receptors |
US7012143B2 (en) | 2002-08-30 | 2006-03-14 | Dombroski Mark A | Cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines |
US7037923B2 (en) | 2002-08-30 | 2006-05-02 | Pfizer, Inc. | Alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines |
US6949652B2 (en) | 2002-08-30 | 2005-09-27 | Pfizer, Inc. | Crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-A]pyridine |
CA2496812A1 (en) * | 2002-08-30 | 2004-03-11 | Pfizer Products Inc. | Novel processes and intermediates for preparing triazolo-pyridines |
PA8579601A1 (es) * | 2002-08-30 | 2004-05-07 | Pfizer Prod Inc | Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas |
US7005523B2 (en) | 2002-08-30 | 2006-02-28 | Pfizer Inc. | Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines |
UA80295C2 (en) * | 2002-09-06 | 2007-09-10 | Biogen Inc | Pyrazolopyridines and using the same |
WO2004060346A2 (en) | 2002-12-30 | 2004-07-22 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
TW200505447A (en) | 2003-02-07 | 2005-02-16 | Daiichi Seiyaku Co | Pyrazole derivative |
EP1601672B1 (en) | 2003-02-14 | 2006-07-26 | Pfizer Products Inc. | Triazolo-pyridines as anti-inflammatory compounds |
TWI326282B (en) * | 2004-04-28 | 2010-06-21 | Mitsubishi Tanabe Pharma Corp | Heterocyclic compound |
CA2570318A1 (en) | 2004-06-30 | 2006-01-12 | Banyu Pharmaceutical Co., Ltd. | Biaryl derivatives |
US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
WO2007092911A2 (en) * | 2006-02-08 | 2007-08-16 | The General Hospital Corporation | Methods, arrangements and systems for obtaining information associated with an anatomical sample using optical microscopy |
ES2301380B1 (es) | 2006-08-09 | 2009-06-08 | Laboratorios Almirall S.A. | Nuevos derivados de 1,7-naftiridina. |
ES2320955B1 (es) | 2007-03-02 | 2010-03-16 | Laboratorios Almirall S.A. | Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida. |
ES2329639B1 (es) | 2007-04-26 | 2010-09-23 | Laboratorios Almirall S.A. | Nuevos derivados de 4,8-difenilpoliazanaftaleno. |
BRPI0810719A8 (pt) * | 2007-04-30 | 2016-03-08 | Abbott Lab | Inibidores da enzima diacilglicerol o-acetiltansferase tipo 1 |
EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
JP5581219B2 (ja) | 2008-01-25 | 2014-08-27 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | チオフェンおよびホスファチジルイノシトール3−キナーゼ(pi3k)阻害薬としてのその使用 |
EP2108641A1 (en) | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
EP2113503A1 (en) | 2008-04-28 | 2009-11-04 | Laboratorios Almirall, S.A. | New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors |
US9090601B2 (en) | 2009-01-30 | 2015-07-28 | Millennium Pharmaceuticals, Inc. | Thiazole derivatives |
CN102395585A (zh) | 2009-01-30 | 2012-03-28 | 米伦纽姆医药公司 | 杂芳基化合物和其作为pi3k抑制剂的用途 |
US8796314B2 (en) | 2009-01-30 | 2014-08-05 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
SI2432767T1 (sl) * | 2009-05-19 | 2013-10-30 | Dow Agrosciences Llc | Spojine in postopki za zatiranje gliv |
EP2322176A1 (en) | 2009-11-11 | 2011-05-18 | Almirall, S.A. | New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives |
MX2013001660A (es) | 2010-08-11 | 2013-06-03 | Millenium Pharmaceuticals Inc | Heteroarilos y usos de los mismos. |
WO2012021611A1 (en) | 2010-08-11 | 2012-02-16 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
WO2012021615A1 (en) | 2010-08-11 | 2012-02-16 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
CA2814688A1 (en) | 2010-10-13 | 2012-04-19 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
AR086113A1 (es) | 2011-04-30 | 2013-11-20 | Abbott Lab | Isoxazolinas como agentes terapeuticos |
WO2017151409A1 (en) | 2016-02-29 | 2017-09-08 | University Of Florida Research Foundation, Incorporated | Chemotherapeutic methods |
JPWO2018159650A1 (ja) * | 2017-02-28 | 2019-12-19 | 東レ株式会社 | グアニジン誘導体及びその医薬用途 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69433501T2 (de) * | 1993-11-08 | 2004-11-04 | Smithkline Beecham Corp. | Oxazole zur behandlung von zytokinvermittelten erkrankungen |
US5658903A (en) * | 1995-06-07 | 1997-08-19 | Smithkline Beecham Corporation | Imidazole compounds, compositions and use |
US5739143A (en) * | 1995-06-07 | 1998-04-14 | Smithkline Beecham Corporation | Imidazole compounds and compositions |
CA2228136A1 (en) * | 1995-08-10 | 1997-02-20 | Merck & Co., Inc. | 2-substituted aryl pyrroles, compositions containing such compounds and methods of use |
US6492516B1 (en) * | 1999-05-14 | 2002-12-10 | Merck & Co., Inc. | Compounds having cytokine inhibitory activity |
-
2000
- 2000-04-11 CO CO00026470A patent/CO5170501A1/es not_active Application Discontinuation
- 2000-04-12 ES ES00922630T patent/ES2202114T3/es not_active Expired - Lifetime
- 2000-04-12 AR ARP000101686A patent/AR023465A1/es unknown
- 2000-04-12 CN CN00807552A patent/CN1378544A/zh active Pending
- 2000-04-12 BR BR0010598-8A patent/BR0010598A/pt not_active IP Right Cessation
- 2000-04-12 PE PE2000000337A patent/PE20010031A1/es not_active Application Discontinuation
- 2000-04-12 HU HU0302747A patent/HUP0302747A2/hu unknown
- 2000-04-12 DK DK00922630T patent/DK1224180T3/da active
- 2000-04-12 CA CA002370417A patent/CA2370417A1/en not_active Abandoned
- 2000-04-12 SK SK1456-2001A patent/SK14562001A3/sk unknown
- 2000-04-12 TR TR2001/02967T patent/TR200102967T2/xx unknown
- 2000-04-12 CZ CZ20013696A patent/CZ20013696A3/cs unknown
- 2000-04-12 PL PL00364789A patent/PL364789A1/xx not_active Application Discontinuation
- 2000-04-12 EP EP00922630A patent/EP1224180B1/en not_active Expired - Lifetime
- 2000-04-12 MX MXPA01010434A patent/MXPA01010434A/es unknown
- 2000-04-12 JP JP2000612294A patent/JP2003503311A/ja active Pending
- 2000-04-12 WO PCT/EP2000/003290 patent/WO2000063204A2/en not_active Application Discontinuation
- 2000-04-12 IL IL14583600A patent/IL145836A0/xx unknown
- 2000-04-12 AU AU42953/00A patent/AU4295300A/en not_active Abandoned
- 2000-04-12 DE DE60003709T patent/DE60003709T2/de not_active Expired - Fee Related
- 2000-04-12 PT PT00922630T patent/PT1224180E/pt unknown
- 2000-04-12 AT AT00922630T patent/ATE244236T1/de not_active IP Right Cessation
- 2000-04-12 KR KR1020017013086A patent/KR20010108504A/ko not_active Application Discontinuation
-
2001
- 2001-10-12 NO NO20014987A patent/NO20014987L/no not_active Application Discontinuation
- 2001-10-12 US US09/975,913 patent/US6579874B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
TR200102967T2 (tr) | 2002-01-21 |
DE60003709D1 (de) | 2003-08-07 |
BR0010598A (pt) | 2002-02-05 |
CA2370417A1 (en) | 2000-10-26 |
CN1378544A (zh) | 2002-11-06 |
ATE244236T1 (de) | 2003-07-15 |
US6579874B2 (en) | 2003-06-17 |
SK14562001A3 (sk) | 2002-03-05 |
AU4295300A (en) | 2000-11-02 |
WO2000063204A3 (en) | 2002-05-23 |
US20020049220A1 (en) | 2002-04-25 |
DK1224180T3 (da) | 2003-10-20 |
AR023465A1 (es) | 2002-09-04 |
JP2003503311A (ja) | 2003-01-28 |
KR20010108504A (ko) | 2001-12-07 |
IL145836A0 (en) | 2002-07-25 |
HUP0302747A2 (hu) | 2003-12-29 |
NO20014987D0 (no) | 2001-10-12 |
NO20014987L (no) | 2001-12-14 |
DE60003709T2 (de) | 2004-12-23 |
PL364789A1 (en) | 2004-12-13 |
PE20010031A1 (es) | 2001-02-23 |
ES2202114T3 (es) | 2004-04-01 |
EP1224180B1 (en) | 2003-07-02 |
EP1224180A2 (en) | 2002-07-24 |
MXPA01010434A (es) | 2002-03-27 |
WO2000063204A2 (en) | 2000-10-26 |
CZ20013696A3 (cs) | 2002-02-13 |
PT1224180E (pt) | 2003-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5170501A1 (es) | AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO | |
IL172993A0 (en) | Thiazolo-,oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinases | |
RU2403250C2 (ru) | Производные пиперидин-4-иламида и их применение в качестве антагонистов рецептора sst подтипа 5 | |
KR890008126A (ko) | 피리다진아민 유도체 | |
RU2005127052A (ru) | Соединения тиенопиримидина и их применение | |
CO5251463A1 (es) | Compuestos heterociclicos y composicion farmaceutica que coniene dichos compuestos | |
CA2223237A1 (en) | 1-phenyl-pyrazole derivatives and their use as parasiticidal agents | |
RU2001121987A (ru) | Замещенные 1-оксо- и 1,3-диоксоизоиндолины и их применение в фармацевтических композициях для снижения уровней воспалительных цитокинов | |
TW200604175A (en) | Ortho substituted aryl or heteroaryl amide compounds | |
EA200101194A1 (ru) | Производные 4,5,6,7-тетрагидроиндазола в качестве противоопухолевых средств | |
RU2372348C2 (ru) | Производные индолилмалеимида в качестве ингибиторов ркс | |
UA42669A (uk) | Антагоністи ангіотензину ii, спосіб їх отримання (варіанти), проміжна сполука (варіанти), спосіб їх отримання та фармацевтична композиція | |
KR970706260A (ko) | 이미다졸 유도체(imidazole derivative) | |
DK0528337T3 (da) | Thiazolylbenzofuranderivater, fremgangsmåde til fremstilling deraf og farmaceutiske præparater, der indeholder disse forbin | |
CO5200785A1 (es) | Uso terapeutico de quinazolina | |
PE20090297A1 (es) | Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis | |
AR047329A1 (es) | Derivados de quinolinas para el tratamiento de enfermedades cardiovasculares. composiciones farmaceuticas | |
PE20030062A1 (es) | Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas | |
RU2007147344A (ru) | Новые производные 2-азетидинона для лечения гиперлипидемических заболеваний | |
TW200519088A (en) | Aryl or heteroaryl amide compounds | |
PE20141075A1 (es) | 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina | |
PE20030702A1 (es) | Inhibidores de pde9 para tratamiento de transtornos cardiovasculares | |
EA200001171A1 (ru) | Бициклические пиримидины и бициклические 3,4-дигидропиримидины как ингибиторы клеточной пролиферации | |
KR900016121A (ko) | 소염제 및 퇴화 억제제로서 유용한 치환된 아제티디논 | |
RU2007147346A (ru) | Новые производные 2-азетидинона в качестве ингибиторов всасывания холестерина для лечения гиперлипидемических состояний |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |